ATNM — Actinium Pharmaceuticals Share Price
Last trade - 00:00- $31.06m
- -$11.06m
- $0.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.48 | ||
| Price to Tang. Book | 13.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 345.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.98% | ||
| Return on Equity | -167.66% | ||
| Operating Margin | -28346.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.14 | 1.03 | 0.08 | n/a | 0.09 | n/a | 12.93 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Directors
- Sandesh Seth CHM (57)
- Steve O'Loughlin CFO (36)
- Avinash Desai OTH
- Arun Swaminathan OTH
- C. David Nicholson LED (66)
- Jeffrey Chell IND (67)
- Ajit Shetty IND (75)
- Richard Steinhart IND (64)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- March 20th, 2013
- Public Since
- March 26th, 2014
- No. of Shareholders
- 100
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 31,374,991
- Address
- 100 Park Ave., 23Rd Floor, NEW YORK, 10017
- Web
- https://www.actiniumpharma.com/
- Phone
- +1 6466773870
- Auditors
- Marcum LLP
Latest News for ATNM
Upcoming Events for ATNM
Q2 2026 Actinium Pharmaceuticals Inc Earnings Release
Q3 2026 Actinium Pharmaceuticals Inc Earnings Release
Actinium Pharmaceuticals Inc Annual Shareholders Meeting
Similar to ATNM
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Apimeds Pharmaceuticals US
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
As of Today at 10:03 UTC, shares in Actinium Pharmaceuticals are trading at $0.99. This share price information is delayed by 15 minutes.
Shares in Actinium Pharmaceuticals last closed at $0.99 and the price had moved by -38.89% over the past 365 days. In terms of relative price strength the Actinium Pharmaceuticals share price has underperformed the S&P500 Index by -48.7% over the past year.
The overall consensus recommendation for Actinium Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreActinium Pharmaceuticals does not currently pay a dividend.
Actinium Pharmaceuticals does not currently pay a dividend.
Actinium Pharmaceuticals does not currently pay a dividend.
To buy shares in Actinium Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.99, shares in Actinium Pharmaceuticals had a market capitalisation of $31.06m.
Here are the trading details for Actinium Pharmaceuticals:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: ATNM
Based on an overall assessment of its quality, value and momentum Actinium Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Actinium Pharmaceuticals is $3.67. That is 270.71% above the last closing price of $0.99.
Analysts covering Actinium Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actinium Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -38.84%.
As of the last closing price of $0.99, shares in Actinium Pharmaceuticals were trading -23.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Actinium Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Actinium Pharmaceuticals' management team is headed by:
- Sandesh Seth - CHM
- Steve O'Loughlin - CFO
- Avinash Desai - OTH
- Arun Swaminathan - OTH
- C. David Nicholson - LED
- Jeffrey Chell - IND
- Ajit Shetty - IND
- Richard Steinhart - IND